Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Nov 26, 2024; 16(11): 944-955
Published online Nov 26, 2024. doi: 10.4252/wjsc.v16.i11.944
Efficacy of serum-free cultured human umbilical cord mesenchymal stem cells in the treatment of knee osteoarthritis in mice
Kai-Zhen Xiao, Gui Liao, Guang-Yu Huang, Yun-Long Huang, Rong-He Gu
Kai-Zhen Xiao, Gui Liao, Guang-Yu Huang, Yun-Long Huang, Rong-He Gu, Department of Orthopedic Surgery, The Fifth Affiliated Hospital of Guangxi Medical University, Nanning 530022, Guangxi Zhuang Autonomous Region, China
Kai-Zhen Xiao, Guang-Yu Huang, Yun-Long Huang, Graduate School of Guangxi Medical University, Guangxi Medical University, Nanning 530022, Guangxi Zhuang Autonomous Region, China
Rong-He Gu, Department of Guangxi Key Laboratory of Intelligent Medicine, The Fifth Affiliated Hospital of Guangxi Medical University, Nanning 530022, Guangxi Zhuang Autonomous Region, China
Co-first authors: Kai-Zhen Xiao and Gui Liao.
Author contributions: Xiao KZ and Gu RH designed the study; Xiao KZ, Liao G, Huang GY, and Huang YL performed the experiments, acquired and analyzed data; Xiao KZ and Liao G interpreted the data; Xiao KZ, Liao G, and Gu RH wrote the manuscript; Xiao KZ and Liao G contributed equally to this work; all authors approved the final version of the article.
Supported by the Cultivated by Outstanding Young Scientific and Technological Innovation and Entrepreneurship Talents in Nanning City, China, No. RC20210107; and Self-Funded Research Project by Guangxi Health Commission, China, No. Z20191090.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Animal Ethics Committee of Guangxi Medical University (IACUC protocol number: Protocol No. 201907878).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rong-He Gu, Doctor, Professor, Department of Orthopedic Surgery, The Fifth Affiliated Hospital of Guangxi Medical University, No. 89 Qixing Road, Qingxiu District, Nanning 530022, Guangxi Zhuang Autonomous Region, China. 201920518@sr.gxmu.edu.cn
Received: April 22, 2024
Revised: September 3, 2024
Accepted: October 18, 2024
Published online: November 26, 2024
Processing time: 217 Days and 20.9 Hours
Core Tip

Core Tip: Mesenchymal stem cells have been shown to alleviate osteoarthritic cartilage and could therefore be used to treat osteoarthritis to reduce or delay the need for knee replacement therapy. This study provides a favorable foundation for the future application of serum-free cultured human umbilical cord mesenchymal stem cells in clinical trials for treating knee osteoarthritis.